Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Aug 17;188(4):619-26.
doi: 10.1084/jem.188.4.619.

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes

A Krause  1 , H F Guo, J B Latouche, C Tan, N K Cheung, M Sadelain
Affiliations

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes

A Krause et al. J Exp Med. .

Abstract

Most tumor cells function poorly as antigen-presenting cells in part because they do not express costimulatory molecules. To provide costimulation to T lymphocytes that recognize tumor cells, we constructed a CD28-like receptor specific for GD2, a ganglioside overexpressed on the surface of neuroblastoma, small-cell lung carcinoma, melanoma, and other human tumors. Recognition of GD2 was provided by a single-chain antibody derived from the GD2-specific monoclonal antibody 3G6. We demonstrate that the chimeric receptor 3G6-CD28 provides CD28 signaling upon specific recognition of the GD2 antigen on tumor cells. Human primary T lymphocytes retrovirally transduced with 3G6-CD28 secrete interleukin 2, survive proapoptotic culture conditions, and selectively undergo clonal expansion in the presence of an antiidiotypic antibody specific for 3G6-CD28. Polyclonal CD8(+) lymphocytes expressing 3G6-CD28 are selectively expanded when cultured with cells expressing allogeneic major histocompatibility complex class I together with GD2. Primary T cells given such an antigen-dependent survival advantage should be very useful to augment immune responses against tumor cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
GD2 expression in Jurkat and EL4 cells. Cells were stained with mAb 3F8 (solid line) or isotype-matched mAb 20.4 (broken line), directed against GD2 and human LNGFR, respectively. (a) Jurkat cells; (b) wild-type EL4; (c) EL4GD2−. The three cell lines are, respectively, GD2 low, GD2 +, and GD2 −. GD2 expression by these cells is closely correlated with the costimulatory activity described in Table 1.
Figure 2
Figure 2
Retroviral gene transfer of 3G6-CD28, 3G6-CD28TR, and NTP in human primary lymphocytes. PBLs were stained 72 h after retroviral infection with antibodies to CD8 (x-axis) and either A1G4 mAb to stain 3G6-CD28 and 3G6-CD28TR or 20.4 mAb to stain NTP (y-axis). Staining with secondary antibody alone (GAR-PE; A) indicates the background staining. Staining with A1G4 (antiidiotype; B and C) and with 20.4 (anti– NTP; D), followed by the corresponding PE conjugates.
Figure 3
Figure 3
3G6-CD28–transduced primary T lymphocytes selectively survive CD3-dependent cell death in the presence of A1G4. Primary T lymphocytes transduced with NTP, 3G6-CD28, or 3G6-CD28TR were kept for 3 d under one of the following conditions: medium without antibody, with OKT3, with OKT3 plus 9.3, or with OKT3 plus A1G4. On day 3, the T cells were released from the cross-linking conditions, and cell viability was measured by trypan blue exclusion and FACS® analysis. The data represent the mean ± SD of four experiments. Cell viability decreased in the presence of the plate-bound OKT3 from 77 ± 9% to 47 ± 7% in the NTP-transduced T cells, and from 77 ± 8% to 56 ± 4 and 54 ± 7% in the 3G6-CD28 and 3G6-CD28TR–transduced groups, respectively. Viability was unchanged by the addition of A1G4 to NTP- and 3G6-CD28TR– transduced T cell groups (51 ± 3 and 53 ± 7%, respectively), but increased to 77 ± 7% in the 3G6-CD28–transduced T cell populations (which were ∼30% A1G4+). Survival in all three groups was comparable in the presence of anti-CD3 and anti-CD28 antibodies (85 ± 8%).
Figure 4
Figure 4
Antiidiotypic mAb A1G4 and cell-bound GD2 provide costimulatory signals to 3G6-CD28–transduced human primary T lymphocytes. (A and B) Primary T lymphocytes transduced with 3G6-CD28 or 3G6-CD28TR were cultured with soluble OKT3 (10 ng/ml) alone or with the addition of soluble A1G4 or 9.3 mAb as described in Materials and Methods. The percentage of transduced cells was measured by FACS® analysis on days 6 and 12. When cultured in the presence of OKT3 and A1G4 antibodies, T lymphocytes transduced with 3G6-CD28 increased from 30% A1G4+ on day 0 to 60% on day 6 and to 88% on day 12, but remained at ∼30% when cultured otherwise (data represent one of three independent experiments). (C and D) HLA A2.1− primary T lymphocytes transduced with 3G6-CD28 (C) or 3G6-CD28TR (D) were cocultured in triplicate wells with irradiated monolayers of fibroblasts as described in Materials and Methods. The fraction of A1G4+ cells was measured by FACS® analysis in both CD4+ and CD8+ subsets on days 6 and 12. In cultures with 3T3-A2.1/GD2 the percentage of CD8+A1G4+ T cells in the 3G6-CD28–transduced population increased from 10 ± 2% on day 0 to 15 ± 2% on day 6 and to 32 ± 4% on day 12 (C). The percentage of CD4+A1G4+ cells in the CD4+ T cell population remained unchanged under all of these coculture conditions (data not shown). Data represent one of three independent experiments.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1–4. - PMC - PubMed
    1. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell. 1995;82:13–17. - PubMed
    1. Boon T, Coulie PD, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267–268. - PubMed
    1. Pardoll DM. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol. 1993;5:719–725. - PubMed
    1. Baskar S. Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunother. 1996;43:165–173. - PubMed

Publication types

MeSH terms